EZH2 and osteosarcoma: We confirmed that miR-138 enhances osteosarcoma cell chemosensitivity by directly targeting EZH2 and that EZH2 overexpression reverses the miR-138–dependent chemosensitivity, which identifies a new direction for chemotherapy.